Cantor Fitzgerald reaffirms Overweight on Abeona Therapeutics, $30 target
Cantor Fitzgerald maintained an Overweight rating on Abeona Therapeutics with a $30.00 price target, implying 436.7% upside versus the Sep 17 close of $5.59.
Story updates
09:55:34 AM UTC
SquawkNews
Ratings actions
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.